Nektar Announces Start of Enrollment in Phase 2 Study of NKTR-181

Nektar Therapeutics NKTR announced today that the first patient has been enrolled in a Phase 2 clinical study of NKTR-181, a new, first-of-its-kind, opioid analgesic candidate. NKTR-181 is a novel mu-opioid agonist molecule designed to have a slow rate of entry into the brain to reduce the attractiveness of the molecule as a target of abuse and to reduce other CNS-mediated side effects, such as sedation and respiratory depression. The Phase 2 study will utilize a double-blind, placebo-controlled, randomized withdrawal study design to assess the efficacy, safety and tolerability of NKTR-181 in patients with moderate to severe chronic pain from osteoarthritis of the knee. Approximately 200 patients will be randomized to receive either NKTR-181 or placebo in the study.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: NewsFDA
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!